Add to Basket Bulk discount
Order hotline:
+1 404 474 4654
+1 888 205 9894 (TF)

Keratin 7 (KRT7) antibody

Antigen

Keratin 7 (KRT7)

Synonyms K7, CK7, SCL, K2C7, MGC3625, MGC129731, Krt2-7, MGC11625, D15Wsu77e, KRT7, MGC137771
Clonality Monoclonal (OVTL12-30)
Host
Alternatives

Mouse

Reactivity
Alternatives

Human

Conjugate
Alternatives Un-conjugated
Application
Alternatives Flow Cytometry (FACS), Immunocytochemistry (ICC), Immunohistochemistry (IHC), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB)
6 references available
Catalog no. ABIN335210
Quantity 1ml  (Variants)
Price 343.20 $   Plus shipping costs $45.00
Bulk discount
Shipping to
Availability Discontinued

Additional Information

Alternative name Cytokeratin 7 / Keratin K7
Immunogen OVTL12/30 is a mouse monoclonal IgG1/kappa antibody derived by fusion of SP2/0-Ag14 mouse myeloma cells with spleen cells from a mouse immunized with a cytoskeletal preparation of OTN-11 ovarian carcinoma cell line.
Isotype IgG1
Clone OVTL12-30
Description Cytokeratins are a subfamily of intermediate filament proteins and are characterized by a remarkable biochemical diversity, represented in human epithelial tissues by at least 20 different polypeptides. They range in molecular weight between 40 kDa and 68 kDa and isoelectric pH between 4.9 - 7.8. The individual human cytokeratins are numbered 1 to 20. The various epithelia in the human body usually express cytokeratins which are not only characteristic of the type of epithelium, but also related to the degree of maturation or differentiation within an epithelium. Cytokeratin subtype expression patterns are used to an increasing extent in the distinction of different types of epithelial malignancies. The cytokeratin antibodies are not only of assistance in the differential diagnosis of tumors using immunohistochemistry on tissue sections, but are also a useful tool in cytopathology and flow cytometric assays.
Specificity Human exclusively.

Application Details

Application Notes OVTL12/30 reacts exlcusively with cytokeratin 7 which is present in specific glandular-type epithelia and most carcinomas derived thereof. OVTL12/30 is effective on frozen tissue after fixation in methanol. It is particularly effective on paraffin-embedded tissue, for which pretreatment with e.g. 0.1% pronase / 0.1% trypsine in PBS or 0.5% pepsine in 0.01N HCl or microwave pretreatment is required. In addition, OVTL 12/30 is suitable for immunocytochemistry,and for immunohistochemistry, with avidin-biotinylated horseradish peroxidase complex (ABC) as detection reagent, immunoblotting and flow cytometry. Optimal antibody dilution should be determined by titration.
Purification Culture supernatant
Storage Store at 4 o C, or in small aliquots at -20 o C.
Restrictions For Research Use only

Publications

Ramaekers, van Niekerk, Poels et al.: "Use of monoclonal antibodies to keratin 7 in the differential diagnosis of adenocarcinomas." in: The American journal of pathology, Vol. 136, Issue 3, pp. 641-55, 1990 (PubMed).

van Niekerk, Jap, Ramaekers et al.: "Immunohistochemical demonstration of keratin 7 in routinely fixed paraffin-embedded human tissues." in: The Journal of pathology, Vol. 165, Issue 2, pp. 145-52, 1992 (PubMed).

van Niekerk, Boerman, Ramaekers et al.: "Marker profile of different phases in the transition of normal human ovarian epithelium to ovarian carcinomas." in: The American journal of pathology, Vol. 138, Issue 2, pp. 455-63, 1991 (PubMed).

van de Molengraft, van Niekerk, Jap et al.: "OV-TL 12/30 (keratin 7 antibody) is a marker of glandular differentiation in lung cancer." in: Histopathology, Vol. 22, Issue 1, pp. 35-8, 1993 (PubMed).

van Niekerk, Vooijs, Casparie-van Velsen et al.: "Differentiation margins of ovarian tumor pathology: first incidences of epithelial ovarian tumors monitored by marker antibodies." in: Cancer detection and prevention, Vol. 21, Issue 3, pp. 247-57, 1997 (PubMed).

Torenbeek, Lagendijk, Van Diest et al.: "Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma." in: Histopathology, Vol. 32, Issue 1, pp. 20. Jul, 1998 (PubMed).